Evaluation of immune response to intravenously administered human | 31005
Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

Evaluation of immune response to intravenously administered human cord blood stem cells in the treatment of symptoms related to chronic inflammation

6th World Congress on Cell & Stem Cell Research

February 29-March 02, 2016 Philadelphia, USA

Brian M Mehling, Louis Quartararo, Marine Manvelyan, Paul Wang and Dong-Cheng Wu

Blue Horizon International LLC, USA
Wuhan University, China
Wuhan Hongqiao Brain Hospital, China

Scientific Tracks Abstracts: J Cell Sci Ther

Abstract :

BHI Therapeutic Sciences, LLC is a healthcare research and consulting company dedicated to the development of stem cell therapies. Our scientific and medical teams are focused on IRB approved protocols, designed to measure the safety and efficacy of intravenous, intra-articular and intrathecal stem cell treatments. The purpose of our study is primarily to monitor the immune response in order to validate the safety of intravenous infusion of human umbilical cord blood derived MSCs (UC-MSCs) and secondly to evaluate effects on biomarkers associated with chronic inflammation. Twenty patients were treated for conditions associated with chronic inflammation and for the purpose of anti-aging. They have been given one intravenous infusion of UC-MSCs. Our study of blood test markers of 20 patients with chronic inflammation before and within three months after MSCs treatment demonstrates that there is no significant changes and MSCs treatment was safe for the patients. Analysis of different indicators of chronic inflammation and aging included in initial, 24 hours, two weeks and three months protocols showed that stem cell treatment was safe for the patients; there were no adverse reactions. Moreover data from follow up protocols demonstrates significant improvement in energy level, hair, nails growth and skin conditions. Intravenously administered UC-MSCs were safe and effective in the improvement of symptoms related to chronic inflammation. Further close monitoring and inclusion of more patients are necessary to fully characterize the advantages of UC-MSCs application in treatment of symptoms related to chronic inflammation.

Biography :

Brian M Mehling is a practicing American Orthopedic Trauma Surgeon, Researcher and Philanthropist. He has started his path in Medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University, completing his degree of Medicine at Wright State University School of Medicine, he has received Post graduate education through Residencies and Fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA. He operates his own practice, Mehling Orthopedics in both West Islip, NY and Hackensack. NJ.